Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study

Kamiya, Tomoya; Uehara, Kay; Nakayama, Goro; Ishigure, Kiyoshi; Kobayashi, Seiichiro; Hiramatsu, Kazuhiro; Nakayama, H.; Yamashita, Keishi; Shimizu, Eiji; Tojima, Yuichiro; Kawai, Satoru; Kodera, Yasuhiro; Nagino, Masato

doi:10.1016/j.ejso.2016.02.014

Cited by 39 publications

(46 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, the response rate was 56.7% and the pCR rate was 6.7%. Previous studies on oxaliplatin-based regimens without a molecular-target drug revealed a pCR rate of 6.6%-12.2% (14,17,18,24). The pCR rate might increase with the addition of a molecular-target drug.…”

Section: Discussionmentioning

confidence: 94%

Feasibility of Neoadjuvant FOLFOX Therapy Without Radiotherapy for Baseline Resectable Rectal Cancer

Koizumi

Yamada

Shinji

et al. 2018

In Vivo

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

Feasibility of Neoadjuvant FOLFOX Therapy Without Radiotherapy for Baseline Resectable Rectal Cancer

Koizumi

Yamada

Shinji

et al. 2018

In Vivo

View full text Add to dashboard Cite

show abstract

“…In rectal cancer, a single published randomized phase III trial was identified, 43 and two randomized phase II studies, 44,45 nine prospective phase II, [46][47][48][49][50][51][52][53][54] and a single retrospective study 55 have been presented/published (►Table 2).…”

Section: Resultsmentioning

confidence: 99%

Neoadjuvant Chemotherapy without Radiation in Colorectal Cancer

Bhudia

Glynne‐Jones

Smith

et al. 2020

Clin Colon Rectal Surg

View full text Add to dashboard Cite

In colon cancer, primary surgery followed by postoperative chemotherapy represents the standard of care. In rectal cancer, the standard of care is preoperative radiotherapy or chemoradiation, which significantly reduces local recurrence but has no impact on subsequent metastatic disease or overall survival. The administration of neoadjuvant chemotherapy (NACT) before surgery can increase the chance of a curative resection and improves long-term outcomes in patients with liver metastases. Hence, NACT is being explored in both primary rectal and colon cancers as an alternative strategy to shrink the tumor, facilitate a curative resection, and simultaneously counter the risk of metastases. Yet, this lack of clarity regarding the precise aims of NACT (downstaging, maximizing response, or improving survival) is hindering progress. The appropriate cytotoxic agents, the optimal regimen, the number of cycles, or duration of NACT prior to surgery or in the postoperative setting remains undefined. Several potential strategies for integrating NACT are discussed with their advantages and disadvantages.

show abstract

“…The advantages of NAC include possible improved OS by introducing intensive chemotherapy (such as FOLFOX and XELOX, including oxaliplatin) at an early stage; reduced postoperative anal dysfunction, postoperative complications, and late effects due to radiation; and a high completion rate of chemotherapy compared to postoperative adjuvant chemotherapy. A summary of reports (10,(12)(13)(14)(15)(16)(17)(18)(19) of pCR rates using NAC and NACRT is shown in Table IV. In recent reports on the effects of NAC on local control, Schrag et al (14) found a pCR rate for the primary lesion of 25% after 6 courses of FOLFOX and bevacizumab, and Kamiya et al (15) reported a pCR rate of 12.2% after 4 courses of XELOX and a rate of 31.7% for a tumor regression grade (TRG) ≥3.…”

Section: Discussionmentioning

confidence: 99%

“…A summary of reports (10,(12)(13)(14)(15)(16)(17)(18)(19) of pCR rates using NAC and NACRT is shown in Table IV. In recent reports on the effects of NAC on local control, Schrag et al (14) found a pCR rate for the primary lesion of 25% after 6 courses of FOLFOX and bevacizumab, and Kamiya et al (15) reported a pCR rate of 12.2% after 4 courses of XELOX and a rate of 31.7% for a tumor regression grade (TRG) ≥3. The pCR rates in these reports and our result of 12.5% for NAC are comparable with results for 5-FU-based NACRT.…”

Section: Discussionmentioning

confidence: 99%

Comparable regional therapeutic effects between neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy for locally advanced lower rectal cancer in terms of histopathological analysis

et al. 2019

View full text Add to dashboard Cite

Neoadjuvant chemoradiotherapy (NACRT) for lower rectal cancer is commonly used in many Western countries. NACRT improves local control, but it may also induce anal dysfunction, postoperative complications, and late effects associated with radiation. Neoadjuvant chemotherapy (NAC) for lower rectal cancer has recently been employed to improve these problems, but the local control effect of NAC when compared with NACRT is controversial. The aim of the present study was to compare the effects of NAC and NACRT using histopathological analysis. The subjects included 16 patients treated with NAC and 10 patients treated with NACRT prior to surgery. Pathological effects on primary lesions and lymph nodes were evaluated based on fibrosis and tumor depth prior to and following preoperative therapy. In the NAC and NACRT groups, the T downgrade rates were 87.5 and 80%, T depth/F depth ratios were 0.61 and 0.73, pathological T downgrade rates were 25 and 40%, pathological complete response rates were 12.5 and 0% for primary lesions and 33.3 and 37.5% for lymph nodes, and the N conversion rates were 80 and 37.5%. There were no significant differences between the groups. These results suggest that the pathological therapeutic effects of NAC were similar to those of NACRT, and NAC may be effective as an alternative therapy to NACRT.

show abstract

Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study

Cited by 39 publications

References 33 publications

Feasibility of Neoadjuvant FOLFOX Therapy Without Radiotherapy for Baseline Resectable Rectal Cancer

Feasibility of Neoadjuvant FOLFOX Therapy Without Radiotherapy for Baseline Resectable Rectal Cancer

Neoadjuvant Chemotherapy without Radiation in Colorectal Cancer

Comparable regional therapeutic effects between neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy for locally advanced lower rectal cancer in terms of histopathological analysis

Contact Info

Product

Resources

About